🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. Mepolizumab

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy Subjects

    phase 1 mab completed

    1 trial

  2. Metabolically Armed CD19 CAR-T cells

    Anhui Provincial Hospital

    Acute Lymphoblastic Leukemia

    phase 1 small molecule active

    1 trial

  3. Metformin

    The First People's Hospital of Lianyungang

    Type2 Diabetes

    phase 1 small molecule active

    1 trial

  4. Methamphetamine (Desoxyn®)

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine Abuse

    phase 1 small molecule completed

    1 trial

  5. Mezagitamab

    Takeda

    Kidney Disease

    phase 1 small molecule completed

    2 trials

  6. Miricorilant 300 mg tablets

    CORCEPT THERAPEUTICS INC

    Healthy

    phase 1 small molecule completed

    1 trial

  7. Mirtazapine 15 mg (Orally Disintegrating) Tablets

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    2 trials

  8. Misoprostol

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hypotonic; Labor

    phase 1 small molecule completed

    1 trial

  9. Mitapivat tablet

    Agios Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  10. Mitapivat tablets

    Agios Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  11. Moexipril HCl/hydrochlorothiazide 15/25 mg tablets

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    2 trials

  12. Mudan granule

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Diabetic Peripheral Neuropathy Type 2

    phase 1 small molecule active

    1 trial

  13. Multiple-Ascending Doses of 2-Methoxyestradiol in Healthy Non-Pregnant Female Participants.

    Laboratorios Tillomed Spain S.L.U

    No medical condition.

    phase 1 other active

    1 trial

  14. Multiple-Dose Bioequivalence of Mirabegron 50 mg Prolonged-Release Tablets in Healthy Participants Under Fasting Conditions.

    Laboratorios Tillomed Spain S.L.U

    No medical condition.

    phase 1 other active

    1 trial

  15. Multiple-Dose Study in Healthy Participants Under Fasting Conditions to Evaluate the Bioequivalence of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide SR 1.5 mg and to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide IR 2.5 mg.

    The George Institute

    No medical condition.

    phase 1 other active

    1 trial

  16. Multiple-Dose Study on the Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diaprel® MR) in Healthy Participants under Fed Conditions.

    The George Institute

    No medical condicion.

    phase 1 other active

    1 trial

  17. Multiple-dose, open-label, laboratory blinded, randomized, 2-period, 2-sequence, crossover, steady-state bioequivalence study comparing the Test Product Naproxen sodium 660 mg modified release tablets with the Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fed conditions.

    Laboratorios Tillomed Spain S.L.U

    No medical condition

    phase 1 other active

    1 trial

  18. NBI-6024

    NEUROCRINE BIOSCIENCES INC

    Type 1 Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  19. NBI-98854 50 mg capsule

    NEUROCRINE BIOSCIENCES INC

    Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects

    phase 1 small molecule completed

    1 trial

  20. NNC0480-0389

    Novo Nordisk A/S

    Healthy Volunteers Type 2 Diabetes

    phase 1 small molecule completed

    1 trial

  21. NT-301 1 mg

    BRIGHT MINDS BIOSCIENCES INC.

    Tolerability of NT-301 Nasal Spray

    phase 1 other completed

    1 trial

  22. Navitoclax

    AbbVie

    Acute Lymphoblastic Leukemia (ALL)

    phase 1 small molecule completed

    1 trial

  23. NeoTISLEGA - A phase Ib trial evaluating the safety and activity of neoadjuvant combination of tislelizumab plus FLOT for resectable esophagogastric adenocarcinoma

    The George Institute

    resectable esophagogastric adenocarcinoma

    phase 1 other active

    1 trial

  24. New formulation

    GlaxoSmithKline

    Herpes Labialis

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources